Innovative liquid formulation, based on the excipient technology.


AQ002S, fixed ICS-LABA combination for nebulization

By reformulating existing ICS and LABA with its proprietary excipient technology, Aquilon Pharma makes ICS-LABA combinations soluble in water. This allows AQ002S to be optimized for any type of Nebulisers.

The answer to today’s needs in the field of asthma medication

Inhaled fixed ICS-LABA combinations are the basic treatment option for asthma patients

ICS-LABA can be delivered via several types of devices, however it is not commonly delivered via nebulization.

Vibrating mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Unfortunately, there is no ICS-LABA in solution available yet for these devices. Aquilon Pharma’s AQ002S liquid formulation (solution) for nebulization is the key.


Aquilon Pharma has strong patents covering its excipient platform up to 2039. Several patents are granted in most of the key countries around the globe.

Medical advantages

Thanks to Aquilon Pharma’s excipient, AQ002S …

  • Shows prolonged airway activity for the same drug concentration
  • Has a better diffusion in the lungs
  • Is more efficient than existing suspensions at a lower dose
  • Improves the efficiency of the administration
  • Minimizes the risk of side effects
  • Minimizes the risk of misuse


Contact us

Do you have a question? Let's get in touch.